Brain research
-
Previous studies have suggested that substance P (SP) plays a critical role in the development of brain oedema and functional deficits following traumatic brain injury and that SP receptor antagonism may improve outcome. No studies have described such a role in ischemic stroke. The present study characterized the effects of the NK1 tachykinin receptor antagonist, n-acetyl-L-tryptophan (NAT), on blood-brain barrier (BBB) breakdown, oedema formation, infarct volume and functional outcome following reversible ischemic stroke in rats. ⋯ Administration of NAT significantly reduced oedema formation and BBB permeability at 24 h post-ischemia and significantly improved functional outcome as assessed over 7 days. There was no effect on infarct volume. We conclude that inhibition of SP activity with a NK1 tachykinin receptor antagonist is effective in reducing cerebral oedema, BBB permeability and functional deficits following reversible ischemia and may therefore represent a novel therapeutic approach to the treatment of ischaemic stroke.
-
Patients with irritable bowel syndrome (IBS) have abnormal cortical responses to rectal distension and grey matter thinning in brain areas associated with nociception. These abnormalities may be driven by white matter changes and individual factors. Therefore, we tested the hypothesis that WM subserving the pain system is compromised in IBS, and that disease characteristics and personality contribute to these abnormalities. ⋯ Pain catastrophizing correlated negatively to cingulum FA in IBS, whereas controls showed correlation between pain catastrophizing and FA of the external capsule adjacent to the left anterior and posterior insula. Thus, fornix and insular white matter is related to IBS symptoms. These data suggest that dysregulation of brain-gut communication via the neuroendocrine pathway or via abnormal visceral sensory and homeostatic input has a role in the pathology of IBS chronic pain.
-
One of the major complications after subarachnoid hemorrhage (SAH) is angiographic vasospasm in the large arteries at the base of the brain. However, a clinical trial of clazosentan demonstrated a 65% relative risk reduction in angiographic vasospasm but no effect on mortality or clinical outcome, raising questions about the role of angiographic vasospasm played in outcome after SAH. The purpose of this study was to determine if reducing or reversing angiographic vasospasm with clazosentan reduced other secondary complications such as microthromboembolism, loss of long-term potentiation (LTP) and neuronal cell death in a rat model of SAH. ⋯ Rats treated with clazosentan had less large-artery vasospsam compared to vehicle-treated controls. However, clazosentan did not prevent the formation of microthromboemboli, neuronal cell death and degeneration and loss of LTP, suggesting there is a dissociation between large-artery angiographic vasospasm and other secondary complications of SAH. This result suggests that alleviation of angiographic vasospasm alone may not be sufficient to prevent other secondary complications or that off-target drug effects after systemic administration of clazosentan counteract the beneficial effects on angiographic vasospasm.
-
Blood-brain barrier (BBB) disruption is a major consequence of cerebral ischemia/reperfusion. Several studies have reported the neuroprotection of pinocembrin on cerebral ischemia in vivo and in vitro, but the effects of pinocembrin on BBB and its underlying mechanisms are not clear. In this study, we investigated the effects of pinocembrin on BBB functions in the global cerebral ischemia/reperfusion (GCI/R) model in rats. ⋯ And pinocembrin alleviated the ultrastructural changes of cerebral microvessels, astrocyte end-feet and neurons, and improved CBF in the GCI/R rats. In addition, pinocembrin increased the viability and mitochondrial membrane potential of cultured RCMECs induced by OGD/R. In conclusion, these data demonstrate that pinocembrin alleviates blood-brain barrier injury induced by GCI/R in rats.
-
Comparative Study
The roles of ionotropic glutamate receptors along the On and Off signaling pathways in the light-adapted mouse retina.
Although the locations of glutamate receptors along the On and Off pathways have been determined, how these receptors modulate the retinal outputs--the light-evoked and spontaneous activities of individual ganglion cells--is not fully understood in the mouse retina. Specifically, how these receptors mediate On and Off responses of retinal ganglion cells in mouse retina under light adaptation remains unknown. Since mouse retina has become a powerful model for vision research, the functions of glutamate receptors along the On and Off pathways in mouse need to be determined. ⋯ We found NMDA and AMPA/KA played different roles in light-evoked EPSCs along On and Off pathways in light-adapted mice retinas. Both NMDA receptor antagonist DL-2-amino-5-phosphonopentanoic acid (AP-5) and AMPA/KA receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) acted on RGCs to reduce On responses of ganglion cells while they acted on Off-cone bipolar cells and/or ganglion cells to mediate Off responses of RGCs. Co-application of AP-5 and CNQX completely eliminated the Off responses in majority of RGCs, indicating that both NMDA and AMPA/KA receptors are critical for light signaling along the cone-driven Off pathways in the light-adapted mouse retina.